CASE ANALYSIS-2
Metabical
Pricing, Packaging & Demand Forecast
For New Weight Loss Drug
1.Discuss Metabical’s points of differentiation compared to current weight loss options?
Metabical is a revolutionary product a
...
CASE ANALYSIS-2
Metabical
Pricing, Packaging & Demand Forecast
For New Weight Loss Drug
1.Discuss Metabical’s points of differentiation compared to current weight loss options?
Metabical is a revolutionary product and forecasted to be the first FDA approved prescriptive
drug for overweight individuals with weight-loss goals. Previous prescriptive drugs had negative
side effects that outweighed its positives. Metabical, on the other hand, did not display as many
negative effects in its trial runs and thus was being strongly endorsed by the medical community.
Current weight-loss drugs can be classified as Prescriptive Drugs or Over-the-counter (OTC)
remedies. OTC drugs were not as popular among overweight individuals due to lack of
regulation and safety concerns. OTC drugs lost out diet plans, exercise plans and meal
replacement/weight management products, as they were safer options.
Metabical was to compete in the Prescriptive drug market, where there were only a few drugs
available but these drugs were mainly approved for obese and severely obese individuals. The
only drug that was approved by the FDA for over-weight individual was for Alli. Alli used to
block the body’s absorption of fat, leading to weight loss. However, it had a lot of side effect
which could cause dangerous medical situations. Metabical on the other hand was a dual layer
controlled release formulation. It acted as an appetite suppressant and also had a fat blocker and
calorie absorption agent. The over-all product was far superior in achieving weight-loss, over its
competitors, for overweight individuals but not for obese and severely obese individuals.
Therefore Metabical was a unique product which was focused towards a particular segment in
the market that is the overweight segment. It was the first of its kind and had that advantage.
There were other products also but they were not as popular in the market segment Metabical
was targeting. It was pictured as a low-risk, high returns drug and had built good support in the
medical community, who were needed to prescribe this drug
2. Metabical could be packaged in counts of 7, 14, 21, 28, (4-week supply), 56(8-week
supply), or 84 (12-week supply).
What considerations should be taken into account when making decisions about the
package count? What package size would you recommend? Why?
A) There are few considerations which should be taken into account before making
decisions, they are:-
Consumers
According to the given data abou
[Show More]